Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.70 |
| ▸ | TPMT | P51580 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | DBH | P09172 | 1/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16884461 | 0.85 | GPR35 (0.65) | GPR35TPMTMAPTGLO1MEN1 | |
| Nitecapone SCHEMBL30489171 | 0.82 | GPR35 (1.00) | GPR35MAPTGLO1EGFRMEN1 | |
| Nitecapone SCHEMBL7039409 | 0.82 | GPR35 (1.00) | GPR35MAPTGLO1EGFRMEN1 | |
| Nitecapone SCHEMBL128420 | 0.82 | GPR35 (1.00) | GPR35MAPTGLO1EGFRMEN1 | |
| SCHEMBL3325762 | 0.81 | XDH (0.63) | GPR35TPMTMAPTDBHEGFR | |
| SCHEMBL7279215 | 0.81 | GPR35 (0.70) | GPR35MAPTEGFRGAATDP1 | |
| SCHEMBL8028708 | 0.81 | GPR35 (0.85) | GPR35MAPTGLO1EGFRMEN1 | |
| SCHEMBL14175318 | 0.76 | TUBB1 (0.68) | TPMTMAPTDBHMEN1ALDH1A1 | |
| SCHEMBL17527235 | 0.76 | TUBB1 (0.68) | TPMTMAPTDBHMEN1ALDH1A1 | |
| SCHEMBL13557412 | 0.74 | TPMT (0.66) | GPR35TPMTMAPTDBHTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0323162-B1 | NEW USE OF CATECHOL-O-METHYL TRANSFERASE (COMT) INHIBITORS AND THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS AND ESTERS | ORION YHTYMAE OY (FI) | 1993-09-15 | — | — | EP | claimed |
| US-5001152-A | Use of catechol-O-methyl transferase (COMT) inhibitors and their physiologically acceptable salts for ulcer treatment | ORION CORPORATION LTD. (FI) | 1991-03-19 | — | — | US | claimed |
| WO-1990002724-A1 | SUBSTITUTED β-DIKETONES | Orion-Yhtymä Oy (FI) | 1990-03-22 | — | — | WO | claimed |
| EP-0323162-A2 | New use of catechol-o-methyl transferase (comt) inhibitors and their physiologically acceptable salts and esters | ORION-YHTYMÀ OY (FI) | 1989-07-05 | — | — | EP | claimed |
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | BISCAYNE NEUROTHERAPEUTICS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-5288750-A | Antiulcer agents for gastrointestinal disorders | ORION-YHTYMA OY (FI) | 1994-02-22 | — | — | US | disclosed |
| EP-0323162-B1 | NEW USE OF CATECHOL-O-METHYL TRANSFERASE (COMT) INHIBITORS AND THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS AND ESTERS | ORION YHTYMAE OY (FI) | 1993-09-15 | — | — | EP | disclosed |
| US-5001152-A | Use of catechol-O-methyl transferase (COMT) inhibitors and their physiologically acceptable salts for ulcer treatment | ORION CORPORATION LTD. (FI) | 1991-03-19 | — | — | US | disclosed |
| WO-1990002724-A1 | SUBSTITUTED β-DIKETONES | Orion-Yhtymä Oy (FI) | 1990-03-22 | — | — | WO | disclosed |
| EP-0323162-A2 | New use of catechol-o-methyl transferase (comt) inhibitors and their physiologically acceptable salts and esters | ORION-YHTYMÀ OY (FI) | 1989-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | HTT, HNMT, GAP43 | GPR35 389/4885TPMT 111/4885MAPT 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.